NEO Beats on revenue estimates by $5+ million, earnings of 7c/share (GAAP, in line with estimates) and is hitting on all cylinders. Third-Quarter Highlights:
Consolidated revenue increased 51% to $104.7 million Clinical Services revenue increased 56% to $92.6 million Pharma Services revenue increased 26% to $12.1 million Pharma Services backlog increased 22% to $118.3 million Gross profit increased 57% to $50.8 million Full-year 2019 guidance increased
The company has revised revenue estimates up (again), and hs solid earnings profile.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.